Results 41 to 50 of about 5,044 (130)

Current trends in drug metabolism and pharmacokinetics. [PDF]

, 2019
Pharmacokinetics (PK) is the study of the absorption, distribution, metabolism, and excretion (ADME) processes of a drug. Understanding PK properties is essential for drug development and precision medication.
Abduljalil, Aghazadeh-Habashi, Aigrain, Aitman, Al Za'abi, Alegre, Alnaqeeb, Aspromonte, Babiskin, Baert, Bakke, Barnett, Bhattacharyya, Cang, Cannady, Cao, Cao, Capecchi, Chen, Chen, Chen, Chen, Chen, Chen, Chen, Cheng, Cheng, Crawford, Currie, De Lange, Dean, Deng, Di Paolo, Dietrich, Diliberto, Dluzen, Dowling, Dragin, Dreisbach, Duan, Edeogu, Edginton, El-Arabey, El-Kadi, EMA, Eum, Falany, Fang, FDA, Feng, Feng, Feng, Ferri, Fleming, Foti, Fox, Freedman, Frye, Fukami, Gaj, Gan, Gao, Gao, Gao, Gao, Gao, Ge, Genovese, Gingell, Gingell, Gong, Graham, Gufford, Guo, Guo, Guo, Guévin, Han, Harrison, Hartz, Hasegawa, He, He, He, He, He, Ho, Ho, Hou, Hsu, Hsueh, Hu, Hu, Hu, Huo, Hwang, Ito, Jacob, Jeong, Jeong, Jia, Jian, Jiang, Jiang, Jiang, Jiang, Jilek, Jilek, Johnson, Jorga, Jung, Kaivosaari, Kalthoff, Kaminsky, Kannan, Karibe, Kesisoglou, Kim, Kim, Knights, Kong, Kota, Kumar, Kurokawa, Lai, Lan, Lanchote, Lee, Lehouritis, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Liang, Lin, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Lopes-Rodrigues, Lu, Lu, Lu, Löfgren, Mano, Marchitti, Margolskee, Martin, Matsson, Mattick, Mazerska, Mei, Mencia, Meng, Min, Mitra, Miyajima, Müller, Nair, Nakano, Nakano, Nakano, Nebert, Nguyen, Niederalt, Nieto Montesinos, Niu, Notenboom, Nozaki, Ohtsuki, Ono, Oostendorp, Pan, Pan, Papageorgiou, Papageorgiou, Park, Pea, Pedersen, Pelkonen, Pellegrino, Pettersson Bergstrand, Qi, Qin, Qiu, Qiu, Raaska, Rives, Riviere, Roberts, Robey, Rocha, Rose, Routy, Rowland, Ruwali, Saini, Satoh, Savage, Scheer, Scheer, Schlender, Schmitt, Schneider, Seitz, Showande, Shu, Shu, Shu, Shugarts, Siu, Song, Staudinger, Strong, Suarez-Sharp, Suh, Suiko, Sukkummee, Sun, Sun, Sutliff, Takeda, Tan, Tan, Tao, Tatsumi, Teorell, Tsai, Tsang, Tsuchiya, Tsume, Tu, Ulldemolins, van Waterschoot, von Richter, Vugmeyster, Vuppugalla, Wagner, Wagner, Wagner, Wang, Wang, Wang, Wang, Wang, Wang, Wang, Wang, Wang, Wang, Wang, Wassenaar, Watanabe, Wei, Wijayakumara, Wilkinson, Wong, Wu, Xia, Xie, Xie, Xu, Xu, Xu, Xu, Xu, Xue, Yamagata, Yamaguchi, Yan, Yang, Yang, Yang, Ye, Yellepeddi, Yi, Yi, Yigitaslan, Yim, Yin, Yoshida, Yoshida, Yoshimi, Yu, Yu, Yu, Yu, Yu, Yu, Yu, Zakeri-Milani, Zanger, Zeng, Zeng, Zhai, Zhang, Zhang, Zhang, Zhang, Zhang, Zhang, Zhang, Zhang, Zhang, Zhao, Zhao, Zhao, Zhao, Zhou, Zhou, Zhou, Zhou, Zhou, Zhu, Zhu, Zhu, Zhuang, Zimmermann   +332 more
core   +1 more source

Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective

Clinical Pharmacology &Therapeutics, Volume 117, Issue 2, Page 403-420, February 2025.
Physiologically‐based pharmacokinetic (PBPK) modeling offers a viable approach to predict induction drug–drug interactions (DDIs) with the potential to streamline or reduce clinical trial burden if predictions can be made with sufficient confidence. In the current work, the ability to predict the effect of rifampin, a well‐characterized strong CYP3A4 ...
Micaela B. Reddy, Tamara D. Cabalu, Loeckie de Zwart, Diane Ramsden, Martin E. Dowty, Kunal S. Taskar, Justine Badée, Jayaprakasam Bolleddula, Laurent Boulu, Qiang Fu, Masakatsu Kotsuma, Alix F. Leblanc, Gareth Lewis, Guiqing Liang, Neil Parrott, Venkatesh Pilla Reddy, Chandra Prakash, Kushal Shah, Kenichi Umehara, Dwaipayan Mukherjee, Jessica Rehmel, Niresh Hariparsad   +21 more
wiley   +1 more source

Personalized medicine : the impact on chemistry [PDF]

, 2010
An effective strategy for personalized medicine requires a major conceptual change in the development and application of therapeutics. In this article, we argue that further advances in this field should be made with reference to another conceptual shift,
Marsh, Andrew, Singer, Donald R. J., Taylor, Paul C., Watkins, John   +3 more
core   +1 more source

Assessment of Potential Drug–Drug Interactions for Novel Oral Melanocortin‐1 Receptor Agonist Dersimelagon

Pharmacology Research &Perspectives, Volume 13, Issue 1, February 2025.
ABSTRACT Dersimelagon is a novel investigational orally administered selective agonist of the melanocortin‐1 receptor. The drug–drug interaction (DDI) potential of dersimelagon was investigated in both nonclinical (in vitro) and clinical studies. The in vitro inhibition of CYP/UGT isoforms and efflux/uptake transporters by dersimelagon was assessed ...
Akihito Ogasawara, Ryosuke Ide, Shinsuke Inoue, Minoru Tsuda, Renli Teng   +4 more
wiley   +1 more source

Inhibition of Tacrolimus Metabolism by Cannabidiol and Its Metabolites In Vitro

Clinical and Translational Science, Volume 18, Issue 2, February 2025.
ABSTRACT Drug interactions are major causes of interindividual variability in tacrolimus exposure and effect. Tacrolimus, a widely used drug in transplant patients, is metabolized by CYP3A4 and CYP3A5. Cannabidiol (CBD) use after transplant is common.
Gerald C. So, Jessica Bo Li Lu, Ying‐Hua Cheng, Debora L. Gisch, Sachiko Koyama, Ricardo Melo Ferreira, Travis R. Beamon, Zeruesenay Desta, Michael T. Eadon   +8 more
wiley   +1 more source

Modeling and predicting drug pharmacokinetics in patients with renal impairment

, 2011
Current guidance issued by the US FDA to assess the impact of renal impairment on the pharmacokinetics of a drug under development has recently been updated to include evaluation of drugs with nonrenal elimination routes.
Aarabi, M., Jamei, M., Rostami-Hodjegan, A., Rowland Yeo, K.   +3 more
core   +1 more source

Influence of Rifampicin on the Pharmacokinetics of the Glucokinase Activator Globalagliatin: A Single‐Center, Open‐Label, Fixed‐Sequence Investigation in Healthy Chinese Volunteers

Journal of Clinical Pharmacy and Therapeutics, Volume 2025, Issue 1, 2025.
Objective: The orally bioavailable glucokinase activator, globalagliatin, is used to improve glucose homeostasis. Its metabolism is primarily dependent on cytochrome P450 (CYP) 3A4. Here, the influence of rifampicin, a potent inducer of CYP3A4 and CYP2C19 inducer, moderate inducer of CYP1A2, CYP2B6, CYP2C8, and CYP2C9, and inhibitor of P‐gp, on the ...
Yaqin Wang, Ya Liu, Maodi Xu, Minhui Wang, Xiaohu Wang, Weijin Liu, Cuilian Jiang, Lin Tan, Suoshuan Liu, Hua Sun, Haitang Xie, Seema Saroj   +11 more
wiley   +1 more source

A translational bioinformatic approach in identifying and validating an interaction between Vitamin A and CYP19A1 [PDF]

, 2015
INTRODUCTION: One major challenge in personalized medicine research is to identify the environmental factors that can alter drug response, and to investigate their molecular mechanisms.
Li, Lang, Li, Zhigao, Philips, Santosh, Skaar, Todd C., Zhou, Jing   +4 more
core   +2 more sources

Polypharmacy and Potential Drug–Drug Interactions in Patients With Atrial Fibrillation

Journal of Clinical Pharmacy and Therapeutics, Volume 2025, Issue 1, 2025.
What is Known and Objective: The use of multiple medications, or polypharmacy, is associated with an elevated risk of potential drug–drug interactions (pDDIs), consequently heightening the probability of adverse drug reactions. Currently, there is a dearth of data regarding pDDIs in Chinese patients with atrial fibrillation (AF) within real‐world ...
Ying Bai, Jianqi Wang, Guangyao Li, Zhen Zhou, Nicholas B. Norgard   +4 more
wiley   +1 more source

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Muscarinic M3 Receptor‐Positive Allosteric Modulator ASP8302 Following Single and Multiple Ascending Oral Doses in Healthy Volunteers

Clinical Pharmacology in Drug Development, Volume 13, Issue 10, Page 1130-1142, October 2024.
Abstract ASP8302 is an orally administered positive allosteric modulator of the muscarinic M3 receptor. Two Phase 1 studies were conducted, a first‐in‐human study in Europe and a Japanese phase 1 study. Both were randomized, participant‐ and investigator‐blinded, placebo‐controlled, single and multiple ascending oral doses, parallel group, clinical ...
Shin Takusagawa, Nicoline Treijtel, Masako Saito, Ingrid Michon, Daisuke Miyatake, Fumio Osaki, Sayuri Guro, Tomasso Fadini, Hisakuni Sekino, Marlous Aarden‐Bakker, Kentaro Kuroishi, Jan Willem Olivier van Till, Dorien Groenendaal‐van de Meent, Michiel de Vries   +13 more
wiley   +1 more source